TG Therapeutics Inc (FRA:NKB2)
€ 51 +0.80 (+1.59%) Market Cap: 7.68 Bil Enterprise Value: 7.89 Bil PE Ratio: 19.97 PB Ratio: 15.00 GF Score: 81/100

Q1 2026 TG Therapeutics Inc Earnings Call Transcript

May 06, 2026 / 12:30PM GMT
Release Date Price: €30.4 (+0.33%)
Operator

Greetings, and welcome to the TG Therapeutics first quarter conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce Jenna Bosco, Chief Communications Officer. Thank you. You may begin.

Jenna Bosco TG Therapeutics Inc;Chief Commercial Officer

Thank you. Welcome, everyone, and thank you for joining us this morning. I'm Jenna Bosco, and with me to discuss TG Therapeutics first quarter 2026 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercial Officer; and Sean Power, our Chief Financial Officer.

Following our safe harbor statement, Mike will begin with an overview of our recent corporate developments. Adam will provide an update on our commercial efforts, and Sean will review our financial results before we open the call for Q&A.

Before we begin, I'd like to remind everyone that today's discussion will include forward-looking statements within the meaning of the Private Securities Litigation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot